curatio (Latin) From cūrō.  
Pronounced cūrātiō (meaning curate/advise)

scientia (Latin) From sciēns.
Pronounced sīˈenchēə (meaning knowledge)

Curatio Scientia Advisors:  An independent consulting 
firm focused on advising the curation of knowledge 
around specialty pharmaceuticals

Thank you for your interest in Curatio Scientia's 2023 Patient Access: State Legal and Regulatory Environment Survey Report.  Please fill in the below information, hit submit and you will be provided a link to download the report.

Our Vision:

To be recognized as the leader in the provision of meaningful, trusted, and independent advisory support in solving for the most pressing industry challenges.

Our Mission:

To leverage our experience, knowledge and network to help develop solutions for industry challenges.  Through such efforts we can play a role in helping to optimize specialty product access and outcomes.

Unique Differentiator:

We combine best in class consulting capabilities with the capacity and perspectives unique to a woman-owned small business* in supporting the overall goals of our clients [*Certifications below]

Commercialization Strategy and Optimization

Our team brings decades of experience in supporting pharmaceutical manufacturers consideration of all aspects of their commercialization solutions for specialty drugs from Phase II through the product lifecycle. We define and vet the landscape and the channel stakeholders needed to support access to the product based on the product's unique attributes. We then facilitate strategic discussions that lead to best in industry commercialization solutions. Examples of our offerings include: - Channel Strategy and Service Model Support (Research, Design, Development, and Implementation - Patient and Provider Journey Mapping (Referral Process Mapping) - Pharmacy Network Design, Modification and Contracting - Patient and Provider Journey Mapping (Referral Process Mapping) - Channel Strategy & Service Models - Research - Design - Development - Implementation - Pharmacy Network Design/Modification - Pharmacy Network Contracting - Therapy Management Services - Specialty Data & Analytics Strategy - Network Data Collection and Reporting - Specialty Network Service Provider Audits - Product Access and Reimbursement

Specialty Pharmaceutical Insights

Our specialty pharmaceutical insights and educational sessions provide detailed analysis of the specialty pharmacy landscape with the opportunity to customize educational sessions for pharmaceutical manufacturers and specialty pharmacies. These educational offerings are built with continual updates and can be curated specific to the audience needs from the C-suite to the field reimbursement and specialty pharmacy level. The format can be virtual as a lecture session or series and can also be live as a workshop. Examples of our offerings are: - US Specialty Pharmacy Landscape - Specialty Pharmacy as a Business/The Economics of Specialty Pharmacy - Key Considerations in Patient Access and Support Services - Strategic Planning and Capital Structure - Operational Build-out - Policy & Procedure Implementation - System Implementation - Specialty Therapy Management - GPO Strategy - Staff Training - Pharmacy Network Contracting - Data and Reporting Solutions - Payor and Pharma Acce

Diligence and Audits

Understanding the specialty pharmaceutical landscape from decades of experience, our team leverages commercialization knowledge and key operational insights provide detailed diligence and analysis at the specialty pharmacy level. This deep dive into all aspects of the operation yields granular level actionable initiative opportunities to bring meaningful value to our clients. Our targeted clients for this type of diligence are private equity firms, pharmaceutical manufacturers and proactive specialty pharmacies. Examples of our offering include: - Pharmacy Service Provider and Specialty Pharmacy Diligence - Network and Data Reporting Assessments - Product Access and Reimbursement Analysis - Market Assessments - Core Product and Services Assessment - Growth and Adjacent Market Opportunities - QOE Validation Support - Procurement Assessment and Optimization - Reimbursement Audit & Validations - State Regulatory, Legislative Assessment - Commercial Health Plan Outlook - Gov’t Reimbursement Outlook - Customer and Key Stakeholder Interviews - Strategic Planning and Capital Structure - Operations and Staffing - Technology, Data and Reporting - Clinical Compliance

Learn More
Trusted Advisors with Competence and Expertise
Curatio Scientia Advisory Network is comprised of our partners, Cheryl, and Jon, and is supported by a network of seasoned, independent pharmaceutical manufacturer consultants and other key resources with deep experience and trusted advisor skills.

If you are interested in learning more about our network for potential participation, please email Cheryl at

Edie Gigot

RN, MSN, MBA Infusion Pharmacy/Suite Lead

Jon Rawlson

Government Affairs Advisor

Randy Falkenrath

MBA, Strategic Advisor

Gary Rice

BS Pharm, MBA Specialty Pharmacy Operations and Clinical

Phyllis Kidder

PharmD Market Access and Payer Strategy

Paul Callahan

MBA Product and Market Diligence Lead

Michael Robbins

BS, BA Market and Patient Access Lead

Harry Travis

BS Pharm, MBA, Strategic Advisor

Luis Rodriguez

MBA, Technology Diligence Lead

Cristin Crane

MBA, CPhT, SSM - Diligence Project Manager

As evidenced by the recent approvals in the Alzheimer's space and coverage issues for gene therapies, any approval other than full traditional FDA approval will lead to access barriers for patients. This must be a key consideration in the commercialization strategy when circumstances align for early approvals.

The pace of innovation in the pharmaceutical pipeline is incredible with novel drug approvals on track to mirror similar annual number of approvals as was seen prior to the pandemic.  While the pace of innovation continues to show strength, the implications on patients’ ability to access the drug based on how the FDA approves a drug is a key consideration.  The recent full approval of LEQEMBI® highlights potential patient access barriers related to the way in which a drug is approved.  From an historical perspective, the plight of treatments in the Alzheimer’s space has been challenging.  The first drug approved in the treatment of Alzheimer’s disease, COGNEX®, a cholinesterase inhibitor, was approved in 1993 but removed from the market in 2013 due to concerns over liver toxicity.  ARICEPT®, approved in 1996 also a cholinesterase inhibitor, however, concerns over questionable Alzheimer’s disease effectiveness clouded the view of stakeholders for its use.  The body of thought around causation of disease shifted research from cholinesterase inhibition to amyloid beta reduction and Biogen’s Aduhelm®, an amyloid beta-directed antibody, was approved in 2021 under conditional approval with much controversy over effectiveness.  This concern over effectiveness resulted in CMS stating that it would decline coverage until the FDA granted full and traditional FDA approval.    LEQEMBI, also an amyloid beta-directed antibody, was approved in January of 2023 however the challenge of CMS remained due to the drug being approved through the FDA’s accelerated pathway.  After further consideration, the FDA granted full traditional approval for LEQEMBI® on July 6, 2023, opening the opportunity for CMS coverage for Medicare patients.  But this is just the beginning, many other barriers to access exist including: 

  • Label indication:  the limitation to early disease with the labeled to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia
  • Black box warning: amyloid related imaging abnormalities (ARIA).  This ARIA occurs more frequently in people with two copies of the APOE gene, which is the gene associated with increased risk of development Alzheimer’s disease discovered through genetic testing.  Genetic testing is a recommendation, not a requirement as treatment and monitoring would not change  (Genetic testing opens up an entirely different conundrum with downstream implications for entire families – we will address this in an additional blog)
  • Patient registry:   CMS-facilitated portal requirement to collect real world evidence to study the usefulness of the drug(s) as all drugs in the same class with full and traditional FDA approval will be required to use
  • Cost:  with projected cost of ~$26,000 annually, Medicare patients would be responsible for 20% coinsurance as on out-of-pocket cost

 Whether in the amyloid beta space or in the broader gene therapy realm, any approval other than full traditional FDA approval will lead to access barriers for patients.  This must be a key consideration in the commercialization strategy when circumstances align for early approvals.  


Novel Drug Approvals for 2023 FDA

LEQEMBI Now Approved

Our team has proven expertise and passion for partnering with pharmaceutical manufacturers in creating solutions to connect innovative specialty pharmaceuticals with patients and caregivers.  


Our advisors, either employed or contracted by Curatio Scientia, LLC, are committed to maintaining the highest ethical standards in our interactions with pharmaceutical manufacturers and all stakeholders involved in pharmaceutical product commercialization, distribution, and support services.  This Code of Conduct outlines the principles that guide our behavior and decision-making.

Compliance with Laws and Regulations

We will comply with all applicable laws, regulations, and industry standards governing our business operations. It is the responsibility of each advisor, either employed or contracted by Curatio Scientia, LLC, to be aware of and adhere to these legal requirements. 

Prohibition of Bribes, Kickbacks, Unlawful Payments, and Other Corrupt Practices

Our advisors are prohibited from directly or indirectly paying anything of value in order to win or retain business or to improperly influence the decision process of an organization; gain an improper advantage; or illegally influence the action of any individual, customer, company, or company representative.  Our advisors are required to keep accurate and transparent records that reflect actual transactions and payments.  While we observe local business customs and market practices, our advisors shall no participate in any corrupt, unethical or illegal practices.  Our advisors comply with all applicable laws and regulations regarding fair competition and antitrust.

Integrity and Honesty

We will conduct all business with integrity, honesty, and transparency. We will not engage in deceptive practices, misrepresentation, or any form of dishonesty.

Accuracy of Business Records

All Curatio Scientia, LLC books and records conform to generally accepted accounting principles.  Our records are legible, transparent and reflect actual transactions and payments.  We will not hide, fail to record, or otherwise make false entries.

Confidentiality and Data Security

We will protect the confidentiality of sensitive information entrusted to us by our clients, partners, and other stakeholders. We will implement and adhere to robust data security measures to ensure the protection of information. 

Conflict of Interest

We will avoid situations that create, or appear to create, a conflict of interest between our personal interests and the interests of our firm or its clients. Any potential conflicts must be disclosed promptly.

Professional Competence and Continual Learning

We will strive for excellence in our work, maintaining a high level of professional competence. We will actively pursue opportunities for continuous learning and professional development to stay informed about industry trends and best practices.

Respect and Diversity

We will treat all individuals with respect, dignity, and fairness, regardless of their background, race, ethnicity, gender, religion, or any other characteristic. We will foster an inclusive and diverse work environment.  We do not permit intimidation or hostility and will not tolerate any behavior that might harass, disrupt or interfere with another person’s ability to work.

Quality of Service

We are committed to delivering high-quality consulting services to our clients. We will work diligently to understand their needs, provide valuable insights, and contribute to the success of their initiatives.

Social Responsibility

We will be socially responsible and contribute positively to the communities in which we operate. This includes considering the environmental impact of our actions and promoting sustainability.

Reporting Violations

Advisors, either employed or contracted by Curatio Scientia, LLC, are encouraged to report any suspected violations of this Code of Conduct promptly. Reports can be made to Cheryl Ann Allen, Founding Partner. Retaliation against individuals reporting in good faith will not be tolerated.


By adhering to this Code of Conduct, we demonstrate our commitment to ethical conduct, professionalism, and the highest standards of integrity. Violations of this Code may result in disciplinary action, up to and including termination of employment and/or other contracted relationship.


Curatio Scientia, LLC, is committed to instituting and maintaining efforts supporting a sustainable future.  Through the individual efforts of each of our advisors, we are improving the sustainability impact on our clients, society, and the environment.  This policy outlines the principles that guide our behavior and decision-making in this area.

Energy Efficiency

We have implemented energy-efficient practices such as LED lighting, energy-efficient appliances, composting, and recycling.  

Telecommuting and Remote Work

We encourage telecommuting and remote work options to reduce the carbon footprint associated with commuting and office energy consumption.  We utilize virtual meeting platforms to minimize travel.

Paperless Office

We strive to minimize paper usage by digitizing documents, utilizing electronic signatures, and implementing cloud-based document storage solutions.

Waste Reduction and Recycling

We support the implementation of recycling and waste reduction initiatives and encourage reusable items such as water bottles.

Sustainable Procurement

We source supplies and equipment from eco-friendly vendors when appropriate.

Green Transportation

We encourage the use of eco-friendly transportation options such as public transit and biking when appropriate.

Community Engagement

We encourage community service activities focused on environmental conservation, such as volunteering for local clean-up efforts or participating in tree-planting initiatives.

Employee Education and Training

We provide ongoing education and training to employees on sustainability practices including workshops and informational resources.

Measurement and Reporting

We annually measure and report on key sustainability metrics to track progress and identify areas for improvement.

Continuous Improvement

We annually review and update our stainability policy, if appropriate, to incorporate best practices to ensure that we remain at the forefront of sustainable business practices.


By implementing this policy, we are demonstrating our commitment to sustainability by reducing environmental impact and contributing to a greener future.